May 18, 2021
PathAI, a Boston-based artificial intelligence pathology company, has closed a Series C funding round worth $165 million.
The round was co-led by D1 Capital Partners and Kaiser Permanente, with additional participation from General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, and strategic partners Bristol-...
November 6, 2019
Boston-based PathAI, maker of artificial intelligence tools for pathology, has capped off its Series B funding round with a $15 million strategic investment from the Merck Global Health Innovation Fund and Bristol-Myers Squibb. This raise brings the startup’s full round to $75 million, and its total funding to just over $90 million.
WHAT THEY DO
PathAI’s platform employs convolutional neural...
April 18, 2019
Yesterday PathAI, a Boston-based maker of artificial intelligence tools for pathology, closed a $60 million Series B funding round led by General Atlantic. Other existing investors, most notably General Catalyst, also participated in the round.
To monitor its investment, General Atlantic Managing Director Dr. Michelle Dipp will also be joining the AI company’s board of directors.
WHAT THEY DO...
November 21, 2018
Last month, Novartis announced that it would be cutting 2,200 jobs as part of a restructuring of the company focusing on particular priorities.
“The overall strategy we have is to focus the company as a leading medicines company powered by digital technologies,” CEO Vas Narasimhan told STAT News last month. “What that has meant is to exit certain health care sectors or segments … — so we exited...